Patent details

Basic Information

Publication number:

LUC00098

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP151514528

Legal Status:

Inactive

Application number:

LUC00098

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/18/1320

Marketing Authorization Type:

Marketing Authorization Date:

29/08/2018

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

28/01/2019

First Marketing Authorization date:

29/08/2018

Grant date:

24/12/2019

Activation date:

Publication date:

31/01/2019

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

29/08/2033

SPC Extension Expiration:

29/08/2033

Rejection date:

Withdrawal date:

Owner

From:

28/01/2019

 

 

Name:

Alnylam Pharmaceuticals, Inc.

Address:

300 Third Street, 3rd Floor, Cambridge, MA 02142, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

28/01/2019

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Publication

Bulletin

1

Bulletin Heading:

SPC1

Bulletin edition number:

2019/02

Publication date:

22/02/2019

Description:

Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:

SPC2

Bulletin edition number:

2020/01

Publication date:

13/01/2020

Description:

Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:

31/10/2029

Annual Fee Number:

21

Annual Fee Amount:

410 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages
31/01/2019	Publication	1
28/01/2019	General Document	2
31/01/2019	Outgoing Correspondence	1
28/01/2019	Application Form	4
24/12/2019	Publication	1
28/01/2019	General Document	3
24/12/2019	Certificate	1
24/12/2019	Outgoing Correspondence	1
28/01/2019	General Document	34